Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985996 · ClinicalTrials.gov registry record · Phase 1
Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02985996 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 48 participants.
The verdict
NCT02985996, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the ability of new anti-HIV agents to penetrate different body compartments in HIV negative men who have sex with men and transgender women. These new agents might be considered for pre-exposure prophylaxis regimens in the future. This study will include 90 healthy, HIV-negative men who have sex with men and transgender women who are not taking hormones aged 18-49 years. Participant must be willing to participate in 1 of the 3 study phases, be willing to take Truvada® (PrEP) or Genvoya®, and willing to undergo blood draws, urethral swabs, and rectal biopsy procedures.
Interventions
- DRUG Truvada
- DRUG Genvoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2017-11-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985996
The ClinicalTrials.gov registry entry for NCT02985996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Truvada is the first listed.
NCT02985996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02985996 about?
NCT02985996 is a clinical study titled "Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities". The purpose of this study is to determine the ability of new anti-HIV agents to penetrate different body compartments in HIV negative men who have sex with men and transgender women. These new agents might be considered for pre-exposure prophylaxis regimens in the future. This study will include 90 ...
What is the current status of trial NCT02985996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2017-02-06. Estimated completion is 2017-11-29.
What interventions are being tested in trial NCT02985996?
The interventions under investigation include: Truvada (DRUG), Genvoya (DRUG).
Who is sponsoring clinical trial NCT02985996?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.